1 Overview and Traditional Understanding of Metformin
Metformin is a versatile biguanide drug. As the first-line therapeutic agent for type 2 diabetes mellitus, it is also one of the most commonly prescribed medicines worldwide, with more than 150 million people globally taking metformin.
For decades, physicians and scientists have held the view that metformin exerts hypoglycemic effects primarily by acting on the liver to inhibit glucose production for the treatment of type 2 diabetes. The prevailing academic consensus long maintained that this biguanide drug administered to millions of patients with type 2 diabetes (T2D) across the globe targets the liver and suppresses hepatic glucose synthesis to control blood glucose. Nevertheless, a mouse-based study led by Northwestern University challenges this consensus. It proposes that this "wonder drug" actually targets the intestine, preventing blood glucose elevation by enhancing glucose utilization in intestinal wall cells.
2 Landmark Publication: Overturning the Traditional Target Hypothesis
On May 8, 2026, researchers from Northwestern University Feinberg School of Medicine published a research paper in Nature Metabolism, a Nature journal. The title of the paper is: Metformin inhibits mitochondrial complex I in intestinal epithelium to promote glycaemic control.
The study reaches a disruptive conclusion: metformin mainly acts on the intestine. By inhibiting mitochondrial complex I in intestinal epithelial cells, the drug improves glucose utilization and thereby curbs blood glucose rises. The research further verifies that mitochondrial complex I in intestinal epithelial cells serves as the core shared therapeutic target for metformin, phenformin and berberine.
Although metformin is widely used clinically for type 2 diabetes, the molecular mechanisms underlying several key pharmacological effects remain unclear, including alleviation of postprandial glycemic excursions and enhanced intestinal glucose uptake. This knowledge gap constitutes an important rationale for carrying out the present study.

3 Elucidation of the Complete Molecular Mechanism of the Intestinal Pathway
In this research, the team integrated publicly available human metabolomic data and orthogonal genetic approaches in male mice, confirming that mitochondrial complex I is the critical target mediating metformin's therapeutic effects in intestinal epithelial cells.
The study proves that metformin suppresses citrulline synthesis; citrulline is a metabolite specifically generated by small intestinal mitochondria. Meanwhile, the drug inhibits mitochondrial respiratory complex I and upregulates the level of growth differentiation factor 15 (GDF15).
Upon inhibition of mitochondrial complex I, the intestine functions as a glucose reservoir, taking up abundant excess glucose, which is subsequently metabolized into lactate and Lac-Phe (a product synthesized from lactate and phenylalanine).
This signaling cascade comprehensively accounts for multiple known clinical observations:
Metformin boosts intestinal glucose consumption and reduces blood glucose;
Citrulline depletion occurs after drug administration;
Postprandial glycemia is improved;
Circulating levels of Lac-Phe and GDF15 increase.
All the above are well-documented clinical manifestations observed during metformin treatment.
4 Mechanism Universality: Beyond Metformin Alone
Extended verification by the research team reveals that phenformin, another biguanide agent, as well as berberine (also known as Huangliansu), a structurally distinct over-the-counter natural compound applied for hypoglycemia, lower blood glucose through the identical pathway.
Synthesizing all experimental findings: mitochondrial complex I in intestinal epithelial cells is a common and pivotal therapeutic target for metformin, phenformin and berberine.
5 Research Implications: Explaining the Multifaceted Pharmacological Effects of Metformin
Apart from hypoglycemic activity, numerous recent studies suggest metformin exerts broad-spectrum potential benefits covering various disorders including cancers, obesity, hepatic diseases and cardiovascular diseases. Furthermore, metformin stands as one of the most intensively investigated candidate compounds for anti-ageing and lifespan extension research.
A critical question has long puzzled academia: how can a single drug, metformin, mediate such diverse biological effects?
The research team puts forward a hypothesis: a drug can regulate multiple physiological processes if it targets a central regulatory hub inside cells, and mitochondria represent such a vital hub. Metformin modulates mitochondrial function via targeted inhibition of mitochondrial complex I, offering a brand-new theoretical explanation for the wide range of potential pharmacological activities of metformin.













